Clinical trial NCT01358474: Detecting Dopaminergic Deficits in Individuals At-risk for Parkinsonism
Official title: Detecting Dopaminergic Deficits in Individuals At-risk for Parkinsonism
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Parkinson Disease
Gaucher Disease
Idiopathic Rapid Eye Movement Sleep Disorder
Keywords: Parkinson disease
idiopathic rapid eye movement sleep disorder
Gaucher disease
healthy volunteer
Lead sponsor: University of Minnesota
Sponsor class: OTHER
Collaborators: name: GE Healthcare
First posted: 2011-05-23
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Investigators' clinical practice (e.g., neurology clinic, sleep disorder clinic, etc).

Brief summary: The purpose of this study is to determine if participants have changes in dopamine cells in their brain using DaTSCAN™ brain imaging. Dopamine cell loss occurs in Parkinson's disease (PD) and other degenerative Parkinsonian disorders, but does not occur in most other movement disorders such as essential tremor or dystonia. DaTSCAN, which is also known as 123I-Ioflupane, is a new compound that has been developed by General Electric, Inc. and has been approved by the US Food and Drug Administration (FDA) to help doctors detect changes in dopamine. This test is performed by injecting DaTSCAN into a vein in the arm, and after a few hours, a large amount of DaTSCAN temporarily accumulates in an area of the brain where there are a lot of dopamine brain cells. Because DaTSCAN contains a small amount of radioactive iodine, it allows doctors to use a special machine called single photon emission computed tomography (SPECT) scanning to detect the location and amount of radioactivity in the brain and help determine if there are changes in brain dopamine. It is hoped that this study will help doctors detect the presence of dopamine changes even before symptoms are present. This study will evaluate DaTSCAN in people with PD, those who are at risk for developing PD (e.g., those with idiopathic rapid eye movement sleep disorder (iRBD) and those who are heterozygous or homozygous for Gaucher's disease (GBA) mutations) and those who are healthy volunteers.


Eligibility criteria: Inclusion Criteria:

* Written consent prior to study by the subject or their surrogate
* Subjects \>/= 18 years and\</=85 years
* Diagnosis of Parkinson's disease, family history of Parkinson's disease, idiopathic rapid eye movement sleep behavioral disorder, age-matched controls, Gaucher's disease or carrier of Gaucher's gene mutation
* Females using adequate methods of birth control or not of childbearing potential

Exclusion Criteria:

* Any clinically significant acute or unstable physical or psychological disease based on medical history or screening physical examination
* Any exposure to investigational drugs within 4 weeks prior to Visit 1
* Any exposure to radiopharmaceuticals within 4 weeks prior to Visit 1
* Pregnancy
* Breastfeeding
* Severe swallowing problems
* Known sensitivity or allergy to iodine containing products
* Advanced liver or renal disease

Primary outcomes:
measure: single photon computed tomography (SPECT) imaging following administration of a visual adjunct imaging agent that detects dopamine loss
timeFrame: Visit 1
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota, Center for Magnetic Resonance Research
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Paul Tuite, MD
role: PRINCIPAL_INVESTIGATOR
References: